35 results
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
and drug creation programs with third parties. * Table of Contents 12
Strategy We believe we represent a new breed of biotechnology company, integrating … discovery. Our Growth Strategy Our goal is to establish our proprietary, end-to-end platform as the industry standard for biologic drug creation. Our growth
424B5
ABSI
Absci Corp
28 Feb 24
Prospectus supplement for primary offering
8:34am
the requirement of a Risk Evaluation and Mitigation Strategy (REMS), to assure the benefits of the product outweigh its risks. A REMS is a safety strategy … or the accompanying base prospectus, other than statements of historical fact, including, without limitation, statements regarding our strategy, future
8-K
ABSI
Absci Corp
27 Feb 24
Results of Operations and Financial Condition
4:45pm
the requirement of a Risk Evaluation and Mitigation Strategy (REMS), to assure the benefits of the product outweigh its risks. A REMS is a safety … strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines
424B5
gz923m
27 Feb 24
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
ncgyi6g20mhklixkulz
8 Jan 24
Absci Corporation 2024 All Rights Reserved 42ND JP Morgan Healthcare Conference
7:08am
8-K
rv66yde8zidcz
14 Aug 23
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
8:13am
8-K
EX-99.1
ix62a5
6 Jun 23
Departure of Directors or Certain Officers
4:08pm
ARS
w6ihgza 4ft
28 Apr 23
Annual report to shareholders
12:00am
PRE 14A
jafbwow 3y8sbd6i6i0
11 Apr 23
Preliminary proxy
5:49pm
8-K
EX-99.1
vzakype oob
30 Mar 23
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
4:10pm
8-K
EX-99.1
tlblvl1
2 Nov 22
Absci Welcomes Meta Senior Executive to Board of Directors
4:06pm
8-K
EX-99.1
6vqp r0pb9fyjrpss
4 Oct 22
Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer
4:09pm